FDA OKs Novel Fixed-Duration Oral Combo for Untreated CLL

(MedPage Today) — The FDA approved acalabrutinib (Calquence) plus venetoclax (Venclexta) for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma as the first all-oral, fixed-duration regimen in the frontline setting…

Source link : https://www.medpagetoday.com/hematologyoncology/leukemia/119970

Author :

Publish date : 2026-02-20 17:14:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

FDA OKs Novel Fixed-Duration Oral Combo for Untreated CLL

Speed Is Seductive. Clinical Trial Certainty Is Slower.

Social Media to Beat Denials; Talking Cancer With Kids; Female Sexual Health Ignored

Related Posts

SSRI Added to Antipsychotics May Raise Cardiac Risk

What NHS challenges does the election winner face?

Carotid Revascularization May Lower Seizure Risk in Stenosis

Is stem cell therapy about to transform medicine and reverse ageing?

Poststroke Epilepsy Carries Higher Risk for Dementia

Assisted dying bill to run out of time as Lords hold final debate

SSRI Added to Antipsychotics May Raise Cardiac Risk

What NHS challenges does the election winner face?

Carotid Revascularization May Lower Seizure Risk in Stenosis

Is stem cell therapy about to transform medicine and reverse ageing?

Poststroke Epilepsy Carries Higher Risk for Dementia

Assisted dying bill to run out of time as Lords hold final debate

Daraxonrasib Combo Shows Promise in First-Line mPDAC

Pioneers Who Changed Clinical Practice

Categories

Archives